Olpasiran associated with reducing bad cholesterol in Cardiovascular Disease
The RNA inhibitor olpasiran significantly reduces a type of bad cholesterol thats associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai researcher of a phase 2 trial. The study reported that higher doses of olpasiran lowered the type of cholesterol called lipoprotein a by more than 95 percent in participants with atherosclerotic cardiovascular disease.










